Albania
Bosnia-Herzegovina
Bulgaria
Croatia
Cyprus
Czech Republic
Denmark
Estonia
Germany
Hungary
Italy
Kosovo
Latvia
Lithuania
Luxembourg
Macedonia
Montenegro
Poland
Portugal
Romania
Serbia
Slovakia
Slovenia
Spain
Switzerland
Sweden
Turkey
United Kingdom
UAE
Hong Kong
Kuwait
Lebanon
South Africa
English 
Български 
Français 
Deutsch 
Ελληνικά 
Magyar 
Italiano 
Cрпски 
Español
Summary
patients treated
Has anyone ever benefited from stem cell?
For the first time, umbilical cord blood cells were successfully used in 1988 in France. Several years later, in 2007, this method was also introduced by FamiCord Group in Poland. So far, umbilical cord blood stem cells have been transplanted over 40,000 times worldwide, saving peoples’ lives and health.
FamiCord Group enables their clients innovative treatment with stem cells. Check the full list of patients, suffered from diverse disorders, who benefited from it.
List of patients
| No. | Source | Source type | Diagnosis | Medical sector | Year of application | Therapy | Country | Age of the recipient |
|---|---|---|---|---|---|---|---|---|
| 301 | Apheresis | Autologous | Non-Hodgkin Lymphoma | Hematology | 2024 | Standard Therapy | Germany | 67 |
| 302 | Apheresis | Allogeneic | Non-Hodgkin Lymphoma | Hematology | 2024 | Standard Therapy | Poland | 46 |
| 303 | Apheresis | Allogeneic | Non-Hodgkin Lymphoma | Hematology | 2024 | Standard Therapy | Poland | 65 |
| 304 | Apheresis | Autologous | Non-Hodgkin Lymphoma | Hematology | 2024 | Standard Therapy | Germany | 66 |
| 305 | Apheresis | Autologous | Non-Hodgkin Lymphoma – relapse | Hematology | 2024 | Standard Therapy | Germany | 54 |
| 306 | Apheresis | Autologous | Nonseminoma | Hematology | 2024 | Standard Therapy | Germany | 38 |
| 307 | Apheresis | Allogeneic | Osteomyelitis | Hematology | 2024 | Standard Therapy | Poland | 65 |
| 308 | Apheresis | Allogeneic | Post-Et-Myelofibrosis | Hematology | 2024 | Standard Therapy | Poland | 59 |
| 309 | Apheresis | Allogeneic | Post-Pv-Myelofibrosis | Hematology | 2024 | Standard Therapy | Poland | 64 |
| 310 | Apheresis | Autologous | Primary Central Nervous System Lymphoma | Hematology | 2024 | Standard Therapy | Germany | 60 |
| 311 | Apheresis | Allogeneic | Primary Myelofibrosis | Hematology | 2024 | Standard Therapy | Poland | 52 |
| 312 | Apheresis | Allogeneic | Primary Myelofibrosis | Hematology | 2024 | Standard Therapy | Poland | 67 |
| 313 | Apheresis | Allogeneic | Primary Myelofibrosis | Hematology | 2024 | Standard Therapy | Poland | 70 |
| 314 | Apheresis | Allogeneic | Relapsed B-Cell Acute Lymphoblastic Leukemia | Hematology | 2024 | Standard Therapy | Poland | 12 |
| 315 | Apheresis | Allogeneic | Severe Aplastic Anemia | Hematology | 2024 | Standard Therapy | Poland | 15 |
| 316 | Apheresis | Allogeneic | Severe Aplastic Anemia | Hematology | 2024 | Standard Therapy | Poland | 10 |
| 317 | Apheresis | Allogeneic | Severe Aplastic Anemia | Hematology | 2024 | Standard Therapy | Poland | 60 |
| 318 | Apheresis | Allogeneic | Severe Aplastic Anemia Progressed To Myelodysplastic Syndrome | Hematology | 2024 | Standard Therapy | Poland | 21 |
| 319 | Skeletal Muscle | Allogeneic – Related | Duchenne Muscular Dystrophy (Dmd) | Genetic disorder | 2023 | Experimental Therapy | Poland | 8 |
| 320 | Skeletal Muscle | Allogeneic – Related | Duchenne Muscular Dystrophy (Dmd) | Genetic disorder | 2023 | Experimental Therapy | Poland | 16 |
| 321 | Cord Tissue | Allogeneic – Related | Ags (Autism + Epilepsy) | Neurology | 2023 | Experimental Therapy | Poland/Romania | 15 |
| 322 | Cord Tissue | Allogeneic – Related | Autism | Neurology | 2023 | Experimental Therapy | Romania | 8,5 |
| 323 | Cord Tissue | Autologous | Autism | Neurology | 2023 | Experimental Therapy | Hungary | 10 |
| 324 | Cord Tissue | Allogeneic – Related | Autism | Neurology | 2023 | Experimental Therapy | Romania | 4 |
| 325 | Cord Tissue | Allogeneic – Related | Autism | Neurology | 2023 | Experimental Therapy | Romania | 10 |
| 326 | Cord Tissue | Allogeneic – Related | Autism | Neurology | 2023 | Experimental Therapy | Romania | 3,2 |
| 327 | Cord Tissue | Autologous | Cerebral Palsy | Neurology | 2023 | Experimental Therapy | Romania | 2 |
| 328 | Cord Tissue | Allogeneic – Related | Cerebral Palsy | Neurology | 2023 | Experimental Therapy | Romania | 3 |
| 329 | Cord Tissue | Allogeneic – Unrelated | Disorders Of Optic Nerve | Ophthalmology | 2023 | Experimental Therapy | Poland | 39,1 |
| 330 | Cord Tissue | Allogeneic – Unrelated | Gonarthrosis | Orthopedy | 2023 | Experimental Therapy | Poland | 65,1 |
| 331 | Cord Tissue | Allogeneic – Unrelated | Gonarthrosis | Orthopedy | 2023 | Experimental Therapy | Poland | 50,8 |
| 332 | Cord Tissue | Allogeneic – Unrelated | Graft Versus Host Disease | Hematology | 2023 | Experimental Therapy | Poland | 8 months |
| 333 | Cord Tissue | Allogeneic – Unrelated | Graft Versus Host Disease | Hematology | 2023 | Experimental Therapy | Poland | 16,2 |
| 334 | Cord Tissue | Allogeneic – Unrelated | Internal Damage To The Knee Joint | Orthopedy | 2023 | Experimental Therapy | Poland | 20,8 |
| 335 | Cord Tissue | Allogeneic – Unrelated | Internal Damage To The Knee Joint | Orthopedy | 2023 | Experimental Therapy | Poland | 49,8 |
| 336 | Cord Tissue | Allogeneic – Unrelated | Internal Damage To The Knee Joint | Orthopedy | 2023 | Experimental Therapy | Poland | 62,7 |
| 337 | Cord Tissue | Allogeneic – Unrelated | Internal Damage To The Knee Joint | Orthopedy | 2023 | Experimental Therapy | Poland | 24,1 |
| 338 | Cord Tissue | Allogeneic – Unrelated | Mucopolysaccharidosis Type Ii | Hematology | 2023 | Experimental Therapy | Poland | 4,7 |
| 339 | Cord Tissue | Allogeneic – Unrelated | Non-Inflammatory Diseases Of The Ovary, Fallopian Tube, And Broad Ligament Of The Uterus | Gynecology | 2023 | Experimental Therapy | Poland | 47 |
| 340 | Cord Tissue | Autologous | Optic Nerve Atrophy, Tetraparesis, Hydrocephalus | Neurology | 2023 | Experimental Therapy | Romania | 5,5 |
| 341 | Cord Tissue | Allogeneic – Unrelated | Ovarian Dysfunction | Gynecology | 2023 | Experimental Therapy | Poland | 44,8 |
| 342 | Cord Tissue | Allogeneic – Unrelated | Ovarian Dysfunction | Gynecology | 2023 | Experimental Therapy | Poland | 32,11 |
| 343 | Cord Tissue | Allogeneic – Unrelated | Polycystic Ovary Syndrome | Gynecology | 2023 | Experimental Therapy | Poland | 39,4 |
| 344 | Cord Tissue | Allogeneic – Related | Right Parietal Closed Schizencephaly | Neurology | 2023 | Experimental Therapy | Romania | 38 |
| 345 | Cord Tissue | Allogeneic – Related | Rp+ Usher Syndrome | Neurology | 2023 | Experimental Therapy | Romania | 10 |
| 346 | Cord Tissue | Allogeneic – Related | Sudden Sensorineural Hearing Loss (Ssnhl) | Neurology | 2023 | Experimental Therapy | Romania | 1 |
| 347 | Cord Blood | Autologous | Autism | Neurology | 2023 | Experimental Therapy | Hungary | 10 |
| 348 | Cord Blood | Allogeneic | Autism | Neurology | 2023 | Experimental Therapy | Poland | 3,3 |
| 349 | Cord Blood | Autologous | Autism | Neurology | 2023 | Experimental Therapy | Romania | 3 |
| 350 | Cord Blood | Autologous | Autism | Neurology | 2023 | Experimental Therapy | Romania | 3 |
| 351 | Cord Blood | Autologous | Autism | Neurology | 2023 | Experimental Therapy | Romania | 10 |
| 352 | Cord Blood | Autologous | Autism | Neurology | 2023 | Experimental Therapy | Portugal | 7 |
| 353 | Cord Blood | Autologous | Autism | Neurology | 2023 | Experimental Therapy | Portugal | 5 |
| 354 | Cord Blood | Autologous | Autism | Neurology | 2023 | Experimental Therapy | Hungary | 14 |
| 355 | Cord Blood | Autologous | Autism | Neurology | 2023 | Experimental Therapy | Romania | 10 |
| 356 | Cord Blood | Autologous | Autism | Neurology | 2023 | Experimental Therapy | Hungary | 3 |
| 357 | Cord Blood | Allogeneic – Related | Autism | Neurology | 2023 | Experimental Therapy | Romania | 3,2 |
| 358 | Cord Blood | Autologous | Autism | Neurology | 2023 | Experimental Therapy | Hungary | 5 |
| 359 | Cord Blood | Allogeneic – Related | Beta Thalassemia | Hematology | 2023 | Standard Therapy | UK | 8 |
| 360 | Cord Blood | Allogeneic – Related | Cerebral Palsy | Neurology | 2023 | Experimental Therapy | Hungary | 5 |
| 361 | Cord Blood | Allogeneic – Related | Cerebral Palsy | Neurology | 2023 | Standard Therapy | UK | 2,5 |
| 362 | Cord Blood | Allogeneic – Related | Cerebral Palsy | Neurology | 2023 | Standard Therapy | UK | 2,5 |
| 363 | Cord Blood | Autologous | Cerebral Palsy | Neurology | 2023 | Experimental Therapy | Poland | 2,1 |
| 364 | Cord Blood | Allogeneic – Related | Cerebral Palsy | Neurology | 2023 | Experimental Therapy | Romania | 10 |
| 365 | Cord Blood | Allogeneic – Related | Cerebral Palsy, Psychomotor Retard, Tetraparesis, Microcephaly | Neurology | 2023 | Experimental Therapy | Romania | 9 |
| 366 | Cord Blood | Autologous | Global Developmental Delay Si Truncal Ataxia | Neurology | 2023 | Experimental Therapy | Romania | 5 |
| 367 | Cord Blood | Allogeneic | Neuroblastoma | Hematology | 2023 | Standard Therapy | Turkey | 2,1 |
| 368 | Cord Blood | Allogeneic – Related | Neuroblastoma | Hematology | 2023 | Standard Therapy | Turkey | 2,1 |
| 369 | Cord Blood | Autologous | Optic Nerve Atrophy, Tetraparesis, Hydrocephalus | Neurology | 2023 | Experimental Therapy | Romania | 5,5 |
| 370 | Cord Blood | Autologous | Pervasive Developmental Disorder | Neurology | 2023 | Experimental Therapy | Poland | 3,11 |
| 371 | Cord Blood | Autologous | Pervasive Developmental Disorder | Neurology | 2023 | Experimental Therapy | Poland | 8,1 |
| 372 | Cord Blood | Allogeneic – Related | Spasmodic Torticollis | Neurology | 2023 | Experimental Therapy | Romania | 41 |
| 373 | Cord Blood | Allogeneic | Thalassemia Major | Hematology | 2023 | Standard Therapy | Turkey | 17,4 |
| 374 | Cord Blood | Allogeneic – Related | Thalassemia Major | Hematology | 2023 | Standard Therapy | Turkey | 17,4 |
| 375 | Cord Blood | Allogeneic | Wiskott-Aldrich Syndrome | Hematology | 2023 | Standard Therapy | Poland | 5 months |
| 376 | Bone Marrow Family | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2023 | Standard Therapy | Poland | 42 |
| 377 | Bone Marrow Family | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2023 | Standard Therapy | Poland | 41 |
| 378 | Bone Marrow Family | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2023 | Standard Therapy | Germany | 35 |
| 379 | Bone Marrow Family | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2023 | Standard Therapy | Poland | 59 |
| 380 | Bone Marrow Family | Allogeneic | Acute Myeloid Leukemia | Hematology | 2023 | Standard Therapy | Poland | 50 |
| 381 | Bone Marrow Family | Allogeneic | Acute Myeloid Leukemia | Hematology | 2023 | Standard Therapy | Poland | 51 |
| 382 | Bone Marrow Family | Allogeneic | Acute Myeloid Leukemia | Hematology | 2023 | Standard Therapy | Poland | 59 |
| 383 | Bone Marrow Family | Allogeneic | Acute Myeloid Leukemia | Hematology | 2023 | Standard Therapy | Poland | 42 |
| 384 | Bone Marrow Family | Allogeneic | Acute Myeloid Leukemia | Hematology | 2023 | Standard Therapy | Poland | 21 |
| 385 | Bone Marrow Family | Allogeneic | Acute Myeloid Leukemia | Hematology | 2023 | Standard Therapy | Poland | 67 |
| 386 | Bone Marrow Family | Allogeneic | Acute Myeloid Leukemia | Hematology | 2023 | Standard Therapy | Poland | 63 |
| 387 | Bone Marrow Family | Allogeneic | Acute Myeloid Leukemia | Hematology | 2023 | Standard Therapy | Poland | 39 |
| 388 | Bone Marrow Family | Allogeneic | Acute Myeloid Leukemia | Hematology | 2023 | Standard Therapy | Poland | 53 |
| 389 | Bone Marrow Family | Allogeneic | Acute Myeloid Leukemia | Hematology | 2023 | Standard Therapy | Poland | 42 |
| 390 | Bone Marrow Family | Allogeneic | Acute Myeloid Leukemia | Hematology | 2023 | Standard Therapy | Poland | 62 |
| 391 | Bone Marrow Family | Allogeneic | Acute Myeloid Leukemia | Hematology | 2023 | Standard Therapy | Poland | 49 |
| 392 | Bone Marrow Family | Allogeneic | Acute Myeloid Leukemia | Hematology | 2023 | Standard Therapy | Poland | 61 |
| 393 | Bone Marrow Family | Allogeneic | Acute Myeloid Leukemia | Hematology | 2023 | Standard Therapy | Poland | 43 |
| 394 | Bone Marrow Family | Allogeneic | Acute Myeloid Leukemia | Hematology | 2023 | Standard Therapy | Poland | 57 |
| 395 | Bone Marrow Family | Allogeneic | Acute Myeloid Leukemia | Hematology | 2023 | Standard Therapy | Poland | 56 |
| 396 | Bone Marrow Family | Allogeneic | Acute Myeloid Leukemia | Hematology | 2023 | Standard Therapy | Poland | 55 |
| 397 | Bone Marrow Family | Allogeneic | Acute Myeloid Leukemia | Hematology | 2023 | Standard Therapy | Poland | 63 |
| 398 | Bone Marrow Family | Allogeneic | Acute Myeloid Leukemia | Hematology | 2023 | Standard Therapy | Poland | 55 |
| 399 | Bone Marrow Family | Allogeneic | Acute Myeloid Leukemia | Hematology | 2023 | Standard Therapy | Poland | 61 |
| 400 | Bone Marrow Family | Allogeneic | Acute Myeloid Leukemia | Hematology | 2023 | Standard Therapy | Poland | 47 |